NASDAQ:ICCC ImmuCell Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.65 +0.39 (+7.41 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$5.27Now: $5.65▼$5.6550-Day Range$4.98MA: $5.40▼$5.9252-Week Range$3.70Now: $5.65▼$8.13Volume24,977 shsAverage Volume45,530 shsMarket Capitalization$40.75 millionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingImmuCell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, ImmuCell has a forecasted upside of 147.8% from its current price of $5.65.Amount of Analyst CoverageImmuCell has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesImmuCell has received 119 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmuCell has received 86 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmuCell has received 58.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote “Outperform” if you believe ICCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.60% of the stock of ImmuCell is held by insiders.Percentage Held by InstitutionsOnly 9.31% of the stock of ImmuCell is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmuCell are expected to grow in the coming year, from ($0.24) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is -21.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is -21.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuCell has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ICCC Previous Symbol CUSIPN/A CIK811641 Webwww.immucell.com Phone207-878-2770Debt Debt-to-Equity Ratio0.31 Current Ratio4.77 Quick Ratio3.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.72 million Price / Sales2.97 Cash Flow$0.15 per share Price / Cash Flow37.94 Book Value$4.02 per share Price / Book1.41Profitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-1,300,000.00 Net Margins-11.75% Return on Equity-5.89% Return on Assets-4.30%Miscellaneous Employees47 Outstanding Shares7,213,000Market Cap$40.75 million Next Earnings Date11/9/2020 (Estimated) OptionableNot Optionable $5.65 +0.39 (+7.41 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ICCC News and Ratings via Email Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. ImmuCell (NASDAQ:ICCC) Frequently Asked Questions How has ImmuCell's stock price been impacted by COVID-19 (Coronavirus)? ImmuCell's stock was trading at $4.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICCC shares have increased by 31.4% and is now trading at $5.65. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ImmuCell? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmuCell. When is ImmuCell's next earnings date? ImmuCell is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020. View our earnings forecast for ImmuCell. How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) announced its quarterly earnings data on Wednesday, August, 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $2.97 million during the quarter. ImmuCell had a negative net margin of 11.75% and a negative return on equity of 5.89%. View ImmuCell's earnings history. What price target have analysts set for ICCC? 1 brokerages have issued twelve-month target prices for ImmuCell's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate ImmuCell's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 147.8% from the stock's current price. View analysts' price targets for ImmuCell. Are investors shorting ImmuCell? ImmuCell saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 6,400 shares, a decrease of 46.2% from the August 15th total of 11,900 shares. Based on an average daily trading volume, of 20,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company's shares are short sold. View ImmuCell's Short Interest. Who are some of ImmuCell's key competitors? Some companies that are related to ImmuCell include Riot Blockchain (RIOT), Biomerica (BMRA), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), Akers Biosciences (AKER), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ). View all competitors. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Biocept (BIOC), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Novavax (NVAX) and Verastem (VSTM). Who are ImmuCell's key executives? ImmuCell's management team includes the following people: Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63) What is ImmuCell's stock symbol? ImmuCell trades on the NASDAQ under the ticker symbol "ICCC." Who are ImmuCell's major shareholders? ImmuCell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perritt Capital Management Inc. (0.83%), RBF Capital LLC (0.18%), Flagship Harbor Advisors LLC (0.17%) and Ingalls & Snyder LLC (0.14%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche. View institutional ownership trends for ImmuCell. Which major investors are selling ImmuCell stock? ICCC stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, and Perritt Capital Management Inc.. View insider buying and selling activity for ImmuCell. Which major investors are buying ImmuCell stock? ICCC stock was purchased by a variety of institutional investors in the last quarter, including RBF Capital LLC, and Flagship Harbor Advisors LLC. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche. View insider buying and selling activity for ImmuCell. How do I buy shares of ImmuCell? Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ImmuCell's stock price today? One share of ICCC stock can currently be purchased for approximately $5.65. How big of a company is ImmuCell? ImmuCell has a market capitalization of $40.75 million and generates $13.72 million in revenue each year. The biotechnology company earns $-1,300,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. ImmuCell employs 47 workers across the globe. What is ImmuCell's official website? The official website for ImmuCell is www.immucell.com. How can I contact ImmuCell? ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
